Project Grant R01AG091310
- Federal Project Grant Award Summary Posit Science Corp received a $1,006,653 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded September 20, 2025, with completion targeted for May 31, 2027. The award funds the INHANCE-MCI (Improving Neurological Health with Acetylcholine via Neuroplasticity-Based Computerized Exercise in Mild Cognitive Impairment) program, a double-blind, parallel-arm, active-controlled clinical trial designed to evaluate a...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded the University of Kansas Center for Research Inc. a $3.23 million Project Grant under the Aging Research program (CFDA 93.866) to investigate the interconnected roles of neuronal activity, synaptic dysfunction, and mitochondrial dysfunction in Alzheimer's disease. The award, issued September 30, 2025, with completion scheduled for August 31, 2029, funds comprehensive biomedical research utilizing mouse models of...
- Federal Project Grant Award Summary The National Institute on Aging (NIA), under its Aging Research program (CFDA 93.866), awarded a $441,612 project grant to the Trustees of Boston University (Boston University Medical Campus) effective May 15, 2025, with a completion date of January 31, 2030. This research initiative investigates the relationship between Life's Essential 8 (LE8)—a quantified set of modifiable lifestyle and clinical risk factors—and digital cognitive markers in predicting...
- Federal Project Grant Award Summary S-3 Research LLC received a $999,556 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective September 20, 2025, with completion targeted for September 19, 2026. The project delivers a multi-modal digital tool designed to improve diversity and inclusivity in Alzheimer's Disease and Related Dementias (ADRD) clinical trial participation. The primary deliverable consists of an integrated platform...
- Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $155,504 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective March 1, 2026, with a completion date of September 7, 2027. This research project investigates the associations between body composition, moderate-to-vigorous physical activity (MVPA), and cognitive function in adults with Down syndrome (DS). The project addresses a...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $336,000 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded September 1, 2025, with a completion date of August 31, 2027. The project evaluates self-reported subjective cognitive concerns (SCC) as an early screening tool for Alzheimer's disease by assessing their relationship with longitudinal Alzheimer's disease biomarkers in a diverse, non-demented older adult...
- Federal Project Grant Award Summary The National Institute on Aging awarded a $10.4 million Project Grant to the Regents of the University of Michigan (Office of Research and Sponsored Projects) under the Aging Research program (CFDA 93.866) to conduct the first clinical study evaluating personalized brain stimulation as a treatment for Posterior Cortical Atrophy (PCA), a neurodegenerative condition typically caused by Alzheimer's disease. The research deliverables include the development and...
- Federal Grant Award Summary Braincheck, Inc. received a $497,782 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded on September 20, 2025, with a completion date of September 19, 2026. The grant funds development of BrainCheck eConsult, a secure digital platform designed to facilitate asynchronous consultations between primary care providers (PCPs) and dementia specialists. The platform will integrate with BrainCheck's existing cognitive...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded a $257,040 Project Grant to the Regents of the University of Michigan, issued June 15, 2025, with a completion date of March 31, 2030, under the Aging Research program (CFDA 93.866). This research initiative aims to advance understanding of Alzheimer's Disease (AD) pathology and its relationship to Mild Behavioral Impairment (MBI) in older adults. The project delivers three core research products: (1) investigation...
- Federal Project Grant Summary The University of Chicago received a $354,727 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective April 1, 2025, through January 31, 2029. The grant supports development of the CAT-COG (Computerized Adaptive Test for Cognition), a novel technology platform designed to assess cognitive function using multidimensional item response theory (MIRT). The deliverable is an adaptive testing system capable of...
The University of Kansas Medical Center Research Institute, Inc. received a $589,614 Project Grant from the National Institute on Aging (Aging Research, CFDA 93.866) effective February 1, 2026, through December 31, 2030, to develop and validate a cognitive safety monitoring system for detecting adverse side effects of anti-amyloid therapies used to treat Alzheimer's disease. The primary deliverable is the Cognitive Monitoring During Treatment for Alzheimer Disease (COMTAD) study, which will administer frequent digital cognitive assessments using the Ambulatory Research in Cognition (ARC) smartphone platform up to three times weekly for approximately 30 weeks to participating patients receiving anti-amyloid therapy. The research will employ changepoint statistical models to evaluate whether acute or long-term cognitive changes correlate with the incidence of amyloid-related imaging abnormalities (ARIA), including analysis of performance variability metrics that may reveal subtle cognitive decline not apparent through conventional assessment approaches. This research addresses a critical gap in current clinical practice by providing a low-cost, patient-friendly alternative to frequent imaging protocols for monitoring cognitive safety during anti-amyloid treatment. The study will generate empirical evidence regarding both acute and long-term cognitive consequences of ARIA events and establish validated protocols for cognitive safety monitoring that can inform future clinical practice standards for Alzheimer's disease management. By leveraging an extensively validated assessment platform, the COMTAD study will enhance clinician capacity to detect treatment-related cognitive adverse events while minimizing burden on patients and clinical staff.Federal Grant Award Summary: COMTAD Study
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $589.6k | 1/20/26 |